BridgeMD
Compares treatment options for Children
Official title Multicentre Randomised Study Comparing a Taurolidine Lock and a Standard Saline Lock in Paediatric Oncology
ClinicalTrials.gov ID: NCT05781295
What this study is testing
- What it's testing
- Interest of a Taurolidine lock at each catheter closure in the primary prevention of catheter-related endoluminal infection in paediatric oncology. Multicentric, controlled, randomized and double-blind label study.
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages up to 21
You may be able to join if
- Patient less than or equal to 21 years of age at inclusion.
- Patient for whom a central catheter is planned to be inserted\ , excluding a non-tunneled femoral or cervical external catheter or a peripherally...
- Patient treated for a cancer.
- Patient with regular follow-up in the inclusion center.
- Informed consent signed by the patient if adult or by legal representatives if minor.
You likely can't join if
- Patient with retinoblastoma.
- Allografted patient.
- Patient with a life expectancy of less than 6 months.
- Patient refusing to participate in the protocol.
- Patient already receiving a central venous catheter-related infection prevention lock (ILCVC).
- Patient with known allergy to citrate or (cyclo)-Taurolidine.
See the full eligibility criteria
- Patient less than or equal to 21 years of age at inclusion.
- Patient for whom a central catheter is planned to be inserted\ , excluding a non-tunneled femoral or cervical external catheter or a peripherally inserted central catheter (as PICC line). \ 1st catheter placement or...
- Patient treated for a cancer.
- Patient with regular follow-up in the inclusion center.
- Informed consent signed by the patient if adult or by legal representatives if minor.
- Patient benefiting from a social security coverage.
- Time between the date of catheter placement and the planned date for the first solution lock injection less than 6 weeks.
- Patient with retinoblastoma.
- Allografted patient.
- Patient with a life expectancy of less than 6 months.
- Patient refusing to participate in the protocol.
- Patient already receiving a central venous catheter-related infection prevention lock (ILCVC).
- Patient with known allergy to citrate or (cyclo)-Taurolidine.
- Patient taking other drugs with a known contraindication with citrate or (cyclo)-Taurolidine.
- Patient with an external femoral catheter.
- Patient with a PICCLINE-type peripheral venous inserted central catheter.
- Patient unable to submit to the medical follow-up of the trial for geographical, social or psychological reasons.
- Patient under guardianship and curatorship.
The study team makes the final eligibility decision.
Where it's taking place
- Paris, France
- Villejuif, France
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, up to 21 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Paris, France; Villejuif, France. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.